Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma

SAN DIEGO, Aug. 30, 2021 -- (Healthcare Sales & Marketing Network) -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutic... Biopharmaceuticals, Oncology, FDA Poseida Therapeutics, multiple myeloma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news